… ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific … medicine platform from David Rodman, MD, who is departing ProQR. Dr. Shams brings to ProQR deep ophthalmology, … provide strategic direction, oversight, and execution for ProQR’s research and early development efforts. This entails …
… ProQR to Present at Scientific and Investor Conferences in … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR to Present at Upcoming JMP Securities Life Sciences … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Eve n ts ”. The archived webcast will …
… ProQR Announces Financial Results for the Third Quarter of … LCA10,” said Daniel A. de Boer, chief executive officer of ProQR. “These results build confidence in QR-110 and the … for QR-110 in patients with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: …
… ProQR Therapeutics Announces Results for the Third Quarter of … today announced results for the third quarter of 2014. "ProQR has made significant accomplishments, both financially … in 2014," said Daniel de Boer, Chief Executive Officer of ProQR. "With the successful completion of our recent initial …
… ProQR Announces Financial Results for the Second Quarter of … said Daniel A. de Boer, chief executive officer of ProQR. “Over the next twelve months, we are looking forward … current cash on hand of €33.0 million (at June 30, 2018), ProQR’s operation is funded into late 2019 Subsequent Events …
… ProQR Therapeutics Announces Results for the First Quarter of … one in a year that is going to be a very exciting one for ProQR," said Daniel de Boer, Chief Executive Officer of ProQR. "We advanced our first pipeline program, QR-110, into …
